SCTIMST Develops Indigenous Coronary Stent 'Chitra Core' with 30-40% Less Metal
2-minute summary
The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), an autonomous institution under the Department of Science and Technology (DST), has unveiled 'Chitra Core', an indigenously developed coronary stent. Built on a Cobalt-Chromium alloy platform, Chitra Core is a polymer-coated Everolimus drug-eluting stent. Its key innovation lies in using 30-40% less metal than conventional stents, which significantly minimizes blood vessel trauma and reduces post-procedure complications such as in-stent restenosis (arterial re-narrowing) and late-stage thrombosis (blood clotting). The manufacturing technology was transferred to Invasive Technologies Pvt. Ltd., which obtained clearance from the Central Drugs Standard Control Organisation (CDSCO). Alongside Chitra Core, SCTIMST has also advanced 'Chitra TiN', a first-of-its-kind bare metal stent coated with Titanium Nitride ceramic. Chitra TiN offers a polymer-free platform that acts as a barrier to prevent nickel ion leaching and adverse tissue-blood reactions. Following the legacy of the 1990 Chitra Heart Valve, these indigenous cardiovascular innovations represent a major milestone in affordable healthcare and biomedical self-reliance under Make in India.
Why it's in the news
SCTIMST announced the commercial soft launch of 'Chitra Core', India's indigenously developed drug-eluting coronary stent with 30-40% less metal content, following manufacturing approval from the CDSCO. It also readied 'Chitra TiN', a novel Titanium Nitride-coated polymer-free stent, for pre-clinical evaluation.
Background and context
Cardiovascular diseases (CVDs) remain the leading cause of mortality in India. Interventional cardiology relies heavily on coronary stents—expandable mesh tubes used to open narrowed coronary arteries. However, conventional metallic and drug-eluting stents present risks: excessive metal mass causes mechanical irritation to vessel walls, polymer coatings may induce long-term inflammation, and bare metal alloys can release trace nickel ions leading to restenosis (re-narrowing) or late-stage thrombosis. Historically, India has been heavily dependent on imported medical devices, resulting in inflated healthcare costs. In 1990, SCTIMST achieved a breakthrough by developing the low-cost Chitra mechanical heart valve, implanted in over two lakh patients. Building on this indigenous R&D expertise and supported by DST's Technical Research Centre for Biomedical Devices, SCTIMST designed Chitra Core and Chitra TiN to overcome foreign reliance and enhance clinical safety.
Constitutional provisions
- Article 21 — Interpreted by the Supreme Court to encompass the right to health and accessible, affordable medical care.
- Article 47 — Directive Principle mandating the State to regard the improvement of public health as among its primary duties.
Government schemes
- Production Linked Incentive (PLI) Scheme for Medical Devices — Aims to boost domestic manufacturing and attract investments in target segments of medical devices including cardiovascular implants.
- Promotion of Medical Device Parks Scheme — Provides world-class common infrastructure facilities to reduce manufacturing costs of indigenous medical devices.
International organisations
- World Health Organization (WHO) — Publishes the Model List of Essential In Vitro Diagnostics and Priority Medical Devices for Cardiovascular Management.
Previous UPSC questions on this theme
- Mains GS-3 2020 — How is science interwoven deeply with our lives? What are the striking changes in agriculture triggered off by the science-based technologies?
Mains practice: India's heavy import dependence on high-end medical devices poses severe challenges to affordable healthcare. In this context, examine the role of indigenous biomedical innovation in achieving healthcare security.
India imports roughly 75-80% of its high-end medical devices, including cardiovascular implants, orthopaedic prosthetics, and advanced imaging systems. This dependency inflates out-of-pocket healthcare expenditure and limits access for marginalized populations.
Significance of Indigenous Biomedical Innovation:
• Cost Reduction and Accessibility: Domestic innovations, like the Chitra Heart Valve and the recently developed 'Chitra Core' coronary stent by SCTIMST, drastically lower treatment costs compared to multinational proprietary alternatives.
• Addressing Local Clinical Needs: Indigenous design can tailor medical devices to Asian anatomical dimensions and local disease phenotypes, improving therapeutic outcomes.
• Mitigation of Supply Chain Disruptions: Domestic production insulates the national healthcare system from geopolitical vulnerabilities and global supply chain bottlenecks.
• Overcoming Clinical Limitations: Advanced domestic R&D allows engineering improvements, such as utilizing Titanium Nitride (TiN) ceramic coatings or reducing metal volume by 30-40% to limit restenosis, nickel leaching, and thrombosis.
Key Challenges to Overcome:
• Lengthy and expensive clinical trial and regulatory approval pathways.
• Bridging the 'valley of death' between laboratory prototypes and commercial mass manufacturing.
• Inadequate indigenous testing and characterization infrastructure compliant with international certification standards.
Way Forward:
To achieve medical device self-reliance, India must strengthen industry-academia translation through institutions like SCTIMST, scale the PLI Scheme for Medical Devices, and upgrade CDSCO's regulatory evaluation capacity. Fostering indigenous innovation is indispensable for realizing universal, affordable, and resilient healthcare under Ayushman Bharat.
Prelims practice questions
Q1. With reference to the medical innovations developed by SCTIMST, consider the following statements: 1. 'Chitra Core' is an indigenously developed coronary stent with 30-40% less metal content than conventional stents. 2. Titanium Nitride (TiN) coating is used in biomedical implants primarily because of its ceramic barrier properties and biocompatibility. 3. The Central Drugs Standard Control Organisation (CDSCO) regulates the manufacturing clearance of medical devices in India. Which of the statements given above are correct?
- 1 and 2 only
- 2 and 3 only
- 1 and 3 only
- 1, 2 and 3
Answer: D. All three statements are correct. Chitra Core uses 30-40% less metal to minimize vessel damage; TiN is an advanced ceramic coating that prevents direct metal contact and nickel leaching; CDSCO is the national regulatory authority in India that grants manufacturing licences for medical devices.
Q2. In the context of interventional cardiology, what does the medical term 'restenosis' refer to?
- Inflammation of the outer lining of the heart
- Re-narrowing or re-occlusion of an artery after stent placement or angioplasty
- Formation of air emboli inside coronary veins
- Rupture of the heart muscle following an infarction
Answer: B. Restenosis refers to the re-narrowing or recurrence of stenosis in a blood vessel after it has been dilated or treated with a stent or angioplasty.
Q3. The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), known for developing the Chitra Heart Valve and coronary stents, is an autonomous institute under which union department/ministry?
- Department of Science and Technology (DST)
- Ministry of Health and Family Welfare
- Department of Biotechnology (DBT)
- Council of Scientific and Industrial Research (CSIR)
Answer: A. SCTIMST is an autonomous Institute of National Importance under the Department of Science and Technology (DST), Government of India.
Revision flashcards
- What is 'Chitra Core'? An indigenous polymer-coated Everolimus drug-eluting coronary stent developed by SCTIMST featuring 30-40% less metal content to minimize arterial damage.
- What is 'Chitra TiN' and what is its unique advantage? A Titanium Nitride (TiN)-coated bare metal stent by SCTIMST; its ceramic barrier prevents direct metal-blood contact, eliminating nickel leaching and reducing thrombosis.
- What is the difference between 'Restenosis' and 'Thrombosis' in stent implantation? Restenosis is the gradual re-narrowing of the stented artery due to tissue growth; Thrombosis is the acute formation of a blood clot within the stent.
- Under which Ministry/Department does SCTIMST function? Department of Science and Technology (DST), Ministry of Science and Technology, Government of India.
- Which statutory body oversees medical device manufacturing licences in India? Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI).